-Next week the important Australian January CPI print is announced on Wednesday, providing more input for the RBA chattering ...

It's been a sad week for CSL Limited (ASX:CSL), who've watched their investment drop 16% to AU$152 in the week since the company reported its interim result. Revenues came in 2.7% below expectations, ...

At five minutes past 4 o’clock on Tuesday afternoon, one of the country’s largest listed companies and an absolute ASX stalwart announced to the sharemarket that its chief executive had resigned. The ...

The worst US flu season in decades did not shield one of Australia’s largest companies, biotechnology firm CSL, from another brutal market response as vaccine scepticism from Trump administration ...

CSL announced the exit of Paul McKenzie as chief executive. Senior executive Gordon Naylor appointed interim CEO. Shares of Australian biotech firm CSL plunged to an 8-year low Wednesday after it ...

Battling lower vaccination rates in the US under the Trump administration’s public health policies and spiralling blood plasma sales in China, Mr Naylor faces a sceptical investment community fretting ...

CSL's underlying earnings fell in the first half, but management stuck to its full-year guidance and boosted the buy-back. The CSL Ltd (ASX: CSL) share price is in focus today after reporting ...

Chairman and former boss Brian McNamee has claimed the departing CEO didn’t have the skills to steer the global biotech’s future. The turmoil at the top adds to a horror six months for CSL. In that ...

CSL Ltd (ASX: CSL) will report its 2026 half-year financial results this morning. The update comes as the company prepares for a change in senior leadership. Just after market close on Tuesday, CSL ...

Australian pharmaceuticals heavyweight CSL has announced its chief executive Dr Paul McKenzie is retiring with immediate effect, as the company tries to rebuild confidence among investors following a ...

With pressure piling on for CSL, the Australian vaccine and plasma specialist has elected to part ways with its CEO on the eve of its latest earnings announcement. Paul McKenzie, Ph.D., who’s served ...

CSL taps ex-vaccine division head Gordon Naylor as interim CEO Appointment of Naylor is a salvage mission, says analyst CSL shares close 5% lower; co to report HY results on Wed Feb 10 (Reuters) - ...